Galectin Therapeutics announces preclinical galectin inhibitor data

Galectin Therapeutics (GALT +3.2%) trades higher after the company says GR-MD-02 and GM-CT-01 demonstrated a "positive therapeutic effect" in NASH with fibrosis.

NASH-induced mice treated with the galectin-inhibitors showed "improved NASH activity and reduced fibrosis including prevention of accumulation of collagen and/or reduced accumulated collagen in the liver."

Data from a first-in-man Phase 1 study of GR-MD-02 is expected early next year. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs